WEBULL
WebtradeDownload

Learn Why The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following Cancer Drug Trial Pact

Simply Wall St · 2d ago
  • On 2 October 2026, AstraZeneca PLC and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to test Datroway with ivonescimab in multiple cancers, beginning with a Phase III trial in first line triple negative breast cancer.
  • The agreement keeps each partner’s development and commercial rights separate while sharing trial costs. This structure reinforces Daiichi Sankyo’s focus on scaling its DXd antibody drug conjugate platform through partnerships rather than fully owned programs.
  • We will look at how Daiichi Sankyo's investment narrative is shaped by the Phase III Datroway and ivonescimab combination collaboration.

Scan beyond Daiichi Sankyo Company and this new oncology partnership by reviewing hand picked 9 healthcare AI stocks that are shaping the next wave of cancer and precision medicine research.

Daiichi Sankyo Company Investment Narrative Recap

Daiichi Sankyo Company invites you to believe that heavy R&D, a broad DXd pipeline and oncology partnerships can justify concentrated exposure to Enhertu and Datroway. The latest Datroway and ivonescimab collaboration fits that story but does not change the basic short term focus, which remains on execution in core breast and lung cancer indications and managing cost of sales.

The biggest near term swing factor still sits in how reliably oncology demand converts into earnings while JPY 80b of CMO fees and ADC related inventory losses weigh on margins. The main risk is simple. If key ADC assets stumble or competition tightens, revenue concentration could bite before cost optimization and in house manufacturing plans fully help.

The fixed income offerings announced on 2 October 2026, totaling ¥116b across unsecured bonds due 2029, 2031 and 2033, matter for this Datroway story. Funding capacity supports a JPY 2.9t R&D plan and more than JPY 200b of cost optimization work without relying only on internal cash flows or equity.

For you as a shareholder, these bonds shape the risk reward mix around execution rather than directionally changing the thesis. Higher borrowing raises financial obligations while giving Daiichi Sankyo Company more room to run large ADC trials, expand manufacturing in Japan, Germany, China and the U.S., and try to convert its oncology pipeline into durable earnings.

What The Analyst Forecasts Assume For Daiichi Sankyo

Daiichi Sankyo Company is being valued on a story that stretches well past the new Datroway and ivonescimab trial. Analyst models hinge on a steady 6.9% annual rise in group revenue over the next three years, a lift in profit margins from 11.8% today to 12.8% by around 2029, and a material step up in earnings.

Consensus forecasts point to earnings of ¥348.3b by 2029, compared with ¥262.9b today. That is an increase of about 33%. The forecast implies that Datroway, Enhertu and the broader DXd portfolio help support higher profit per yen of sales at the same time as absolute profit grows.

These profit expectations are not tight around a single number. The most optimistic analysts see earnings in 2029 closer to ¥476.6b, while the most cautious expect around ¥238.7b. For you as a holder or potential holder, that spread speaks to genuine uncertainty about how ADC uptake, price pressure and cost controls will play out.

On top of the profit story, forecasts build in a modest reduction in share count, with analysts assuming the number of shares falls by about 1.66% a year for the next three years. If that happens, per share metrics like earnings per share get an extra lift, even before considering any change in overall profit.

Valuation assumptions then layer on top. To line up with the current analyst case, you would need to accept that by 2029 Daiichi Sankyo Company generates about ¥2,718.7b of sales, earns ¥348.3b in profit and trades on a P/E of 23.5x. That would be higher than the 18.4x multiple used today and well above the current 13.9x P/E sitting on the broader JP Pharmaceuticals sector.

Daiichi Sankyo Company's narrative projects ¥2,718.7b revenue and ¥348.3b earnings by 2029. This requires 6.9% yearly revenue growth and about 33% earnings increase from ¥262.9b today.

Discover why Daiichi Sankyo Company's fair value indicates a 54% potential upside to its current price, which could close faster than many investors expect.

TSE:4568 1-Year Stock Price Chart
TSE:4568 1-Year Stock Price Chart

Exploring Other Perspectives

You are not the only one wondering how this new Datroway and ivonescimab tie up could reshape Daiichi Sankyo Company. The most optimistic analysts were already pencilling in around ¥3,152.0b of revenue and ¥476.5b of earnings by 2029, well above consensus, before this news hit. Those views may shift again as the story develops.

Explore 2 other Daiichi Sankyo Company fair value estimates, including one that suggests as much as 128% potential increase from the current price!

The Verdict Is Yours

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking for more investment ideas beyond Daiichi Sankyo Company?

If the Datroway story has sharpened your view on oncology exposure, it can help to compare Daiichi Sankyo Company with other businesses that match your risk and return preferences. The Simply Wall St Screener lets you quickly filter for different profiles so you can build a watchlist that fits the way you invest.

  • If you want income potential with payouts above cash rates, scan a curated set of 32 dividend fortresses that combine yield with underlying business strength.
  • If capital preservation matters more to you than big swings, focus on 22 resilient stocks with low risk scores that aim to balance steadier fundamentals with measured growth ambitions.
  • If you prefer to hunt for underfollowed opportunities, filter for 72 high quality undiscovered gems that pair solid balance sheets with under-the-radar market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.